Alnylam third quarter income boosts from $24.2 million to $27.7 million Alnylam Pharmaceuticals, Inc http://levitrainorge.com . , a leading RNAi therapeutics company, reported its consolidated financial results for the third quarter ended September 30 today, 2010, and company highlights. Indeed, our improvement this quarter now brings us a pipeline of three RNAi therapeutics in clinical development. Specifically, we initiated our Phase I study of ALN-TTR01 for the treatment of transthyretin-mediated amyloidosis, and we continuing enrolling patients inside our ALN-VSP Phase I study in liver cancer individuals and our ALN-RSV01 Phase IIb study in RSV-contaminated adult lung transplant patients,’ stated John Maraganore, Ph.D., CEO of Alnylam.
Schebesta and his analysis team discovered that, in particular, measurements of the pharyngeal airspace differed between actual sufferers and all the simulators significantly. Differences were found when comparing how big is the oral airspace also, the horizontal size of the tongue and the distance from the epiglottis to the trunk of the pharyngeal wall structure. With the results of this trial, we display that none of the investigated manikins displays the anatomic details of humans adequately, said Dr. Schebesta. Consequently, the conclusions drawn by others, who used these manikins as replacements for actual patients, need to be questioned.